4BIO Capital

4BIO Capital is a London-based venture capital firm focused exclusively on the advanced therapies sector. Operating as a trading name of 4BIO Partners LLP , the firm invests in and builds early-stage companies developing treatments in areas of high unmet medical need, with a goal of ensuring broad patient access to potentially curative therapies. Its investment focus spans cell and gene therapy, RNA-based therapy, targeted therapies, and microbiome-based treatments. The team combines leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in journals including Nature, The Lancet, and the New England Journal of Medicine. 4BIO targets eight to twelve companies per fund, primarily at Seed and Series A stages, and invests across the UK, Europe, and the US. The firm has a track record of leading rounds, including co-leading a $75.5M Series A for Actithera and leading an oversubscribed £61M Series A for Cytospire Therapeutics. LPs include healthcare institutions, family offices, and strategic investors from the US, Japan, and Europe.